AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34653252
Drug: Crinecerfont 100
RxNorm normalized name: crinecerfont 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinecerfont 100 mg twice daily for 14 days
Trial: 34653252
Drug: Crinecerfont 100
RxNorm normalized name: crinecerfont 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinecerfont 100 mg once daily at bedtime for 14 days
Trial: 34653252
Drug: Crinecerfont 100
RxNorm normalized name: crinecerfont 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinecerfont 100 mg once daily in the evening for 14 days
Trial: 34653252
Drug: Crinecerfont 50
RxNorm normalized name: crinecerfont 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinecerfont 50 mg once daily at bedtime for 14 days
Trial: 34653525
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug treatments without LD-RT
Trial: 34654283
Drug: Pharmaceutical recommendations
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical recommendations by clinical pharmacists
Trial: 34654283
Drug: Diuretic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic therapy recommendations
Trial: 34654464
Drug: Individual Placement
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Placement and Support (IPS) plus treatment as usual (TAU)
Trial: 34655570
Drug: EGCG solution
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG solution
Trial: 34655570
Drug: EGCG solution
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG solution with casein addition
Trial: 34655683
Drug: Baseline AAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline AAA volume, tortuosity, MTD, current tobacco use, angiotensin II receptor blocker use, and history of diabetes mellitus
Trial: 34656148
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction (DR) of IL-17 and IL-23 inhibitors, with dosing intervals prolonged stepwise to achieve 66% and 50% of the original dose.
Trial: 34656173
Drug: Internet-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based occupational therapy intervention 'Strategies for Empowering activities in Everyday life' (SEE, version 1.0)
Trial: 34657389
Drug: Perampanel 4
RxNorm normalized name: perampanel 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 4 mg/d during the Maintenance Period
Trial: 34657389
Drug: Perampanel 4
RxNorm normalized name: perampanel 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 4 mg/d during the Titration Period
Trial: 34659081
Drug: Prasinezumab, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasinezumab, dosage and duration not available
Trial: 34659208
Drug: Allocetra™-OTS (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allocetra™-OTS (early apoptotic cell) infusion
Trial: 34659886
Drug: Sintilimab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab monotherapy (2/3 L cohorts)
Trial: 34659886
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus chemotherapy (1 L cohorts)
Trial: 34659886
Drug: Sintilimab (2/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (2/3 L cohorts)
Trial: 34659886
Drug: Sintilimab alone
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab alone or combined with chemotherapy
Trial: 34660302
Drug: Neoadjuvant Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Chemotherapy (NCT) including adriamycin plus cyclophosphamide followed by intravenous docetaxel for 24 weeks
Trial: 34660302
Drug: Neoadjuvant Endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Endocrine Therapy (NET) involving goserelin acetate and daily tamoxifen for 24 weeks
Trial: 34660654
Drug: KOKO Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOKO Plus (macronutrient- and micronutrient-fortified complementary food supplement)
Trial: 34661885
Drug: upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 15 mg QD and 30 mg QD
Trial: 34662285
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) delivered via telemental health; details on dosage and duration not specified.
Trial: 34663208
Drug: UST trough
RxNorm normalized name: Ustell
DrugBank: Phenyl salicylate (DB11071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UST trough concentration > 1.12 μg/mL
Trial: 34663479
Drug: Initial serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial serum lactate > 5 mmol/L
Trial: 34663479
Drug: Initial serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial serum lactate ≤ 5 mmol/L
Trial: 34663638
Drug: Tremelimumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (75 mg intravenous) plus Durvalumab (1500 mg intravenous) every 4 weeks (up to four doses), followed by Durvalumab maintenance every 4 weeks (up to nine doses)
Trial: 34663638
Drug: Post-treatment evaluation
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment evaluation of the bone microenvironment
Trial: 34663650
Drug: Intensive rehabilitation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive rehabilitation programme (including physical, occupational, and speech therapy)
Trial: 34664183
Drug: Microgynon (ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microgynon (ethinylestradiol 30 μg and levonorgestrel 150 μg) administered before nintedanib and after nintedanib 150 mg twice daily for ≥ 10 consecutive days.
Trial: 34664427
Drug: Mevidalen (titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mevidalen (titration from 15 to 75 mg)
Trial: 34664531
Drug: Lanreotide PRF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide PRF (prolonged-release formulation) administered every 12 weeks
Trial: 34664789
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (AAD) after catheter ablation for paroxysmal AF (n = 1051)
Trial: 34664789
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (AAD) after catheter ablation for persistent AF (n = 641)
Trial: 34664789
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic drug therapy (AAD) after catheter ablation for paroxysmal AF (n = 1087)
Trial: 34664789
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic drug therapy (AAD) after catheter ablation for persistent AF (n = 496)
Trial: 34665002
Drug: Immune-based treatment
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune-based treatment
Trial: 34665781
Drug: ABCB5+ MSCs
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABCB5+ MSCs (2 × 10^6 cells/kg) administered via 3 i.v. infusions on days 0, 17, and 35
Trial: 34665810
Drug: Single 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 400 mg oral dose of Albendazole (ALB)
Trial: 34665942
Drug: RC48 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC48 2.5 mg/kg alone every 2 weeks
Trial: 34666214
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with regional hyperthermia
Trial: 34666347
Drug: CD30 CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD30 CAR T-cell therapy (CD30.CAR-T)
Trial: 34666347
Drug: High metabolic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High metabolic tumor volume (MTV > 60 mL) before lymphodepletion and CD30.CAR-T infusion
Trial: 34666347
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to bridging therapy
Trial: 34666347
Drug: Percentage of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percentage of CD3+PD-1+ lymphocytes over the first 6 weeks of therapy
Trial: 34666382
Drug: Maternal surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal surface electrode patch
Trial: 34668977
Drug: Camrelizumab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab at 200 mg IV Q2W
Trial: 34669164
Drug: Regular, twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular, twice-weekly voluntary PCR testing of health-care workers (HCW) and visitors in interventional nursing homes (INH)
Trial: 34669183
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI; Acthar) 80 U subcutaneously twice weekly for 12 weeks followed by a 4-week taper
Trial: 34670025
Drug: Continuation Magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation Magnetic Seizure Therapy
Trial: 34670169
Drug: Pembrolizumab maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab maintenance therapy after ASCT
Trial: 34670762
Drug: 30-item prefinal
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-item prefinal questionnaire administered electronically or by paper sheet.
Trial: 34671131
Drug: Vinflunine 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinflunine 320 mg/m², 4 cycles
Trial: 34671764
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Group Therapy
Trial: 34672246
Drug: CD79-targeted chimeric
RxNorm normalized name: Chimeric Antigen Receptor T Cells targeting CD7
DrugBank: PA3-17 (DB18569)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD79-targeted chimeric antigen receptor (CAR) T-cell therapy
Trial: 34673442
Drug: Bosutinib 400
RxNorm normalized name: bosutinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 400 mg/day
Trial: 34673442
Drug: Bosutinib 300
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 300 mg/day
Trial: 34673442
Drug: Bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 500 mg/day (matched controls)
Trial: 34673442
Drug: Bosutinib (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib (dose reduction)
Trial: 34674490
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg nightly for 8 weeks
Trial: 34674742
Drug: mRNA vaccine
RxNorm normalized name: RSV mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA vaccine Comirnaty® (Pfizer/BioNTech)
Trial: 34674742
Drug: COVID-19 mRNA
RxNorm normalized name: COVID-19 mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 mRNA Vaccine Moderna®
Trial: 34675018
Drug: Video game
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Video game therapy (VGT) on commercial video game console, 1 hour training session over 4 weeks (three sessions/week)
Trial: 34675018
Drug: Video game
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Video game therapy (VGT)
Trial: 34675018
Drug: Video game
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Video game therapy (VGT) and Standardised balance platform training (BPT)
Trial: 34675020
Drug: Standard post-TP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard post-TP care and treatment
Trial: 34675050
Drug: Progression index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progression index model based on tertiles of circulating concentrations of biomarkers (osteopontin, matrix metallopeptidase-7, intercellular adhesion molecule-1, periostin)
Trial: 34675131
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment only
Trial: 34675131
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment trends
Trial: 34675476
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (RBZ) treatment, pro re nata regimen, mean number of injections 5.18 (range 2-6)
Trial: 34675476
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (RBZ) treatment in non-vitrectomized eyes (group 2)
Trial: 34675644
Drug: Fu's subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu's subcutaneous needling (FSN) treatment
Trial: 34675644
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation treatment
Trial: 34675644
Drug: FSN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSN treatment
Trial: 34676191
Drug: Daily disinfection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disinfection of the endoscopy unit
Trial: 34678156
Drug: Overall positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall positive predictive value of biopsy using PSA threshold of 3.0 ng/mL
Trial: 34678156
Drug: Overall positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall positive predictive value of PSA threshold of 3.0 ng/mL
Trial: 34678678
Drug: Trastuzumab alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab alone (4 mg/kg initial dose then 2 mg/kg weekly for 5 weeks)
Trial: 34678678
Drug: Trastuzumab combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab combined with everolimus (10 mg/day for 6 weeks)
Trial: 34678870
Drug: IC14 (atibuclimab)
RxNorm normalized name: IC14, (RECOMBINANT CHIMERIC MAB AGAINST HUMAN CD14)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC14 (atibuclimab) 2 mg/kg IV followed by 1 mg/kg/d IV × 3 (n=3)
Trial: 34678870
Drug: IC14 (atibuclimab)
RxNorm normalized name: IC14, (RECOMBINANT CHIMERIC MAB AGAINST HUMAN CD14)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC14 (atibuclimab) 4 mg/kg IV followed by 2 mg/kg/d IV × 3 (n=7)
Trial: 34684360
Drug: FIT2 program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIT2 program (smoking cessation therapy with individualized coaching in diet and physical activity strategies for PCWG restriction)
Trial: 34686372
Drug: Maternal serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal serum albumin (MAlb) level <36.1 g/L
Trial: 34686372
Drug: Maternal serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal serum albumin (MAlb) level >36.1 g/L
Trial: 34686556
Drug: Daily screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily screening for sepsis using the 2007 American Burn Association diagnostic criteria
Trial: 34686556
Drug: Daily multiple
RxNorm normalized name: Daily Multiple Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multiple organ dysfunction syndrome and Sequential Organ Failure Assessment Scores
Trial: 34686642
Drug: PTSD comorbidity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTSD comorbidity after 6 weeks of antidepressant use
Trial: 34687040
Drug: Bamlanivimab 175-500
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab 175-500 mg
Trial: 34687412
Drug: MRI measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI measures of subcutaneous adipose tissue in women with BCRL
Trial: 34688250
Drug: Larotinib 350
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larotinib 350 mg
Trial: 34688250
Drug: Larotinib 250
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larotinib 250 mg and 300 mg
Trial: 34688250
Drug: Larotinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larotinib (all doses)
Trial: 34688250
Drug: Larotinib (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larotinib (350 mg)
Trial: 34688291
Drug: Quit Card
RxNorm normalized name: danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quit Card Intervention (QCI) - includes a 'Quit Card' worth $300 for nicotine replacement therapy, a self-help booklet, and 6 months of telephone follow-up counseling.
Trial: 34690831
Drug: Transcranial Direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Direct Current Stimulation (tDCS), details on dosage and duration not available
Trial: 34691243
Drug: Capecitabine in
RxNorm normalized name: Product containing capecitabine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine in combination with bendamustine
Trial: 34692470
Drug: TTFields/TMZ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTFields/TMZ combination
Trial: 34692470
Drug: TMZ monotherapy
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ monotherapy
Trial: 34693288
Drug: Macitentan 30
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan 30 mg to 300 mg once daily with TMZ
Trial: 34693505
Drug: Tolvaptan (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (15 mg/day, median treatment duration 18.5 days, range 1-1130 days)
Trial: 34693508
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy initiated before the age of 5 years
Trial: 34693508
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy initiated after the age of 5 years
Trial: 34693508
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy achieving > 95% clearance
Trial: 34693720
Drug: Ajmaline test
RxNorm normalized name: ajmaline
DrugBank: Ajmaline (DB01426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ajmaline test (1 mg/kg over 5 minutes)
Trial: 34693994
Drug: Adjunctive counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive counseling by a health professional other than the physician
Trial: 34693994
Drug: Cost-free smoking
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-free smoking cessation medications
Trial: 34694435
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in hs-cTnT values exceeding the biological variation defined by MID
Trial: 34694529
Drug: Sasanlimab (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sasanlimab (intravenous at 1, 3, or 10 mg/kg every 3 weeks)
Trial: 34694529
Drug: Sasanlimab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sasanlimab (subcutaneous at 300 mg every 4 weeks)
Trial: 34694529
Drug: Sasanlimab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sasanlimab (both intravenous and subcutaneous)
Trial: 34694911
Drug: Transcranial Rotating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Rotating Permanent Magnet Stimulator (TRPMS), 10 consecutive 40-minute treatment sessions.
Trial: 34695615
Drug: Same-day intraprostatic
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day intraprostatic fiducial marker placement, perirectal hydrogel injection, and CT and MRI simulation
Trial: 34696785
Drug: internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered cognitive behavioral therapy (iCBT) program combined with exercise therapy and education
Trial: 34696785
Drug: exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exercise therapy and education
Trial: 34697109
Drug: Nadroparin overlapped
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin overlapped with warfarin